Drug Approvals, Clinical Trials, Awards, Offerings, and Earnings - Research Report on J&J, Sanofi, Novartis, BioScrip, and Pacira

NEW YORK, August 19, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Sanofi (NYSE: SNY), Novartis AG (NYSE: NVS), BioScrip Inc. (NASDAQ: BIOS), and Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On August 8, 2013, Janssen-Cilag International NV (Janssen), a pharmaceutical company of Johnson & Johnson (J&J), announced that it has received an approval from the European Commission (EC) for the use of VELCADE (bortezomib) as an induction therapy (a first therapeutic option) in combination with dexamethasone (VD) or thalidomide and dexamethasone (VTD) in adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation. The approval is based on the analysis of results from two Phase III trials (IFM-2005-01, PETHEMA/GEM05) which showed that treatment with VELCADE-based induction therapy improved post-induction and post-transplant response rates and progression-free survival. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-15/JNJ]

--

Sanofi Research Report

On August 5, 2013, Sanofi announced that its vaccine division, Sanofi Pasteur, has initiated a Phase III clinical program, Cdiffense, to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI or C. diff). John Shiver PhD, Senior Vice President for Research & Development at Sanofi Pasteur, commented, "With the emergence of difficult-to-manage strains of C. diff, CDI has become more frequent, more severe and more difficult to treat in recent years, raising concerns about how to control it and prevent transmission." Shiver added, "Vaccination could be an efficacious, cost-effective and important public-health measure to protect individuals from C. diff." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-15/SNY]

--

Novartis AG Research Report

On August 8, 2013, Novartis AG (Novartis) announced that it is the first company to have been awarded global 'CEO Cancer Gold Standard' accreditation by the non-profit organization CEO Roundtable on Cancer, a group of cancer fighting CEOs from various industries, including healthcare. Joseph Jimenez, CEO of Novartis, stated, "At Novartis, we believe that everyone should have access to early screening programs and innovative therapies." Jimenez continued, "Our efforts for our associates, which are recognized by this designation, are an extension of our goal to redefine cancer for all patients." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-15/NVS]

--

BioScrip Inc. Research Report

On August 14, 2013, BioScrip Inc. (BioScrip) announced the upsizing and pricing of its registered underwritten public offering of common stock. BioScrip reported that the upsizing was from 6,800,000 shares to 6,895,873 shares, all of which will be sold by selling stockholders. The Company added that the underwriter of the offering has been granted an option, exercisable within 30 days, to purchase up to an additional 1,020,000 shares of common stock from the selling stockholders on the same terms and conditions. BioScrip also reported that it expects the offering to be close on or about August 19, 2013, subject to customary closing conditions. The Full Research Report on BioScrip Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-15/BIOS]

--

Pacira Pharmaceuticals, Inc. Research Report

On August 6, 2013, Pacira Pharmaceuticals, Inc. (Pacira) released its Q2 2013 financial results. Total revenues were up 38.9% YoY to $17.1 million. Net loss was $14.0 million, or diluted loss per share of $0.42, in Q2 2013, compared to a net loss of $8.3 million, or diluted loss per share of $0.27, in Q2 2012. Commenting on the results, Dave Stack, President, CEO, and Chairman of Pacira, said, "The second quarter marks the commencement of the second year of launch, and we are pleased with the strong sales growth and traction of EXPAREL." Stack added, "Broad market acceptance across a wide range of surgical specialties, bolstered by a series of commercial initiatives and a growing body of clinical evidence, has led to formulary approval and expanded access among both existing and new customers alike." The Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-15/PCRX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports